After digging through discards, biotech startup is making a $45M bet it can fix a failed cancer therapy
The results were clear: Naptumomab estafenatox failed to prolong overall survival for renal cell carcinoma patients in a large trial, definitively enough that Active Biotech effectively shelved it in 2013.
But three years later NeoTX, a scavenger startup that had been digging through drugs that failed in hopes of finding a subpopulation with a biomarker that the original developer had missed, stumbled upon the data and saw the unexpected gem they were looking for.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.